PD-1/PD-L Axis in Neuroinflammation: New Insights

The approval of immune checkpoint inhibitors (ICIs) by the Food and Drug Administration (FDA) led to an improvement in the treatment of several types of cancer. The main targets of these drugs are cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein-1/programmed death-ligand 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Manenti, Susanna, Orrico, Mario, Masciocchi, Stefano, Mandelli, Alessandra, Finardi, Annamaria, Furlan, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9222696/
https://www.ncbi.nlm.nih.gov/pubmed/35756927
http://dx.doi.org/10.3389/fneur.2022.877936

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9222696/
https://www.ncbi.nlm.nih.gov/pubmed/35756927
http://dx.doi.org/10.3389/fneur.2022.877936

Ejemplares similares